Biotech Jonathan Saltzman — Boston Globe STAT Plus: UCB’s $2.5 billion purchase of Ra Pharma underscores immunology focus
Biotech Damian Garde, Rebecca Robbins and Adam Feuerstein STAT Plus: After Sarepta, going after the genetic causes of epilepsies at Stoke
